131 related articles for article (PubMed ID: 38002612)
1. Influence of Brain Metastasis on Analgesia-Related Outcomes in Patients with Lung and Breast Cancers Treated with Naldemedine: A Propensity Score-Matched Analysis.
Hanamoto A; Koseki T; Utsunomiya A; Ishihara T; Tobe T; Kondo M; Kijima Y; Matsuoka H; Mizuno T; Hayashi T; Yamada S
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002612
[TBL] [Abstract][Full Text] [Related]
2. Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: A nationwide retrospective cohort study in Japan.
Abe H; Sumitani M; Matsui H; Inoue R; Fushimi K; Uchida K; Yasunaga H
Pharmacotherapy; 2022 Mar; 42(3):241-249. PubMed ID: 34967450
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies.
Osaka I; Ishiki H; Yokota T; Tada Y; Sato H; Okamoto M; Satomi E
ESMO Open; 2019; 4(4):e000527. PubMed ID: 31423335
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.
Kamiya T; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984494
[No Abstract] [Full Text] [Related]
6. Naldemedine and Magnesium Oxide as First-Line Medications for Opioid-Induced Constipation: A Comparative Database Study in Japanese Patients With Cancer Pain.
Kessoku T; Higashibata T; Morioka Y; Naya N; Koretaka Y; Ichikawa Y; Hisanaga T; Nakajima A
Cureus; 2024 Mar; 16(3):e55925. PubMed ID: 38601408
[TBL] [Abstract][Full Text] [Related]
7. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
8. Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain.
BouSaba J; Sannaa W; Camilleri M
Therap Adv Gastroenterol; 2022; 15():17562848221078638. PubMed ID: 35509419
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Profile of Naldemedine, a Peripherally Acting
Kanemasa T; Koike K; Takase K; Arai T; Nakamura A; Morioka Y; Hasegawa M
J Pharmacol Exp Ther; 2020 Jun; 373(3):438-444. PubMed ID: 32169839
[TBL] [Abstract][Full Text] [Related]
10. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.
Kanemasa T; Koike K; Arai T; Ono H; Horita N; Chiba H; Nakamura A; Morioka Y; Kihara T; Hasegawa M
Neurogastroenterol Motil; 2019 May; 31(5):e13563. PubMed ID: 30821019
[TBL] [Abstract][Full Text] [Related]
12. Naldemedine-induced opioid withdrawal syndrome with severe psychiatric symptoms in an advanced cervical cancer patient without brain metastasis.
Ishida M; Hiraoka M; Yaguchi A; Sugano K; Adachi N; Itoga T; Ishiguro T; Onishi H
Palliat Support Care; 2022 Jun; 20(3):445-447. PubMed ID: 34955117
[TBL] [Abstract][Full Text] [Related]
13. Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets.
Kanemasa T; Matsuzaki T; Koike K; Hasegawa M; Suzuki T
Life Sci; 2020 Sep; 257():118048. PubMed ID: 32622946
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
[TBL] [Abstract][Full Text] [Related]
15. [Effect of enterostomy on analgesic pattern in patients with advanced digestive tract cancer].
Ling JY; Li YY; Zhong LX; Li WW; Liu H; Cai Y; Hu HB; Zhang JW; Deng YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1159-1164. PubMed ID: 31874532
[No Abstract] [Full Text] [Related]
16. Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ-opioid receptor antagonist.
Watari R; Matsuda A; Ohnishi S; Hasegawa H
Drug Metab Pharmacokinet; 2019 Apr; 34(2):126-133. PubMed ID: 30770183
[TBL] [Abstract][Full Text] [Related]
17. Naldemedine for the Use of Management of Opioid Induced Constipation.
Urits I; Patel A; Kiernan HC; Clay CJ; Monteferrante N; Jung JW; Berger AA; Kassem H; Hasoon J; Kaye AD; Kaye AM; Viswanath O
Psychopharmacol Bull; 2020 Jul; 50(3):97-118. PubMed ID: 32733114
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients.
Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Kaira K; Minato K
Thorac Cancer; 2022 Aug; 13(16):2301-2308. PubMed ID: 35790500
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study.
Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Minato K; Obayashi K
J Clin Med; 2022 May; 11(9):. PubMed ID: 35566798
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
Esmadi M; Ahmad D; Hewlett A
J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
